Skip to main content

Peer Review reports

From: Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

Original Submission
18 Apr 2022 Submitted Original manuscript
11 May 2022 Reviewed Reviewer Report - Rita Costa
15 May 2022 Reviewed Reviewer Report - Murat Acat
26 May 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 2
26 May 2022 Submitted Manuscript version 2
8 Aug 2022 Reviewed Reviewer Report
15 Aug 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 3
15 Aug 2022 Submitted Manuscript version 3
19 Aug 2022 Reviewed Reviewer Report
24 Aug 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 4
24 Aug 2022 Submitted Manuscript version 4
19 Oct 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 5
19 Oct 2022 Submitted Manuscript version 5
28 Oct 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 6
28 Oct 2022 Submitted Manuscript version 6
5 Nov 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 7
5 Nov 2022 Submitted Manuscript version 7
10 Nov 2022 Author responded Author comments - Yuta Nio
Resubmission - Version 8
10 Nov 2022 Submitted Manuscript version 8
Publishing
16 Nov 2022 Editorially accepted
30 Nov 2022 Article published 10.1186/s12890-022-02249-8

You can find further information about peer review here.

Back to article page